
The BonEnza trial evaluated whether adding zoledronic acid (ZA) to enzalutamide (E) plus androgen deprivation therapy (ADT) improves bone response in metastatic hormone-sensitive prostate cancer (mHSPC). Among 126 patients assessed via WB-DW-MRI, overall response rates were identical in both arms (69.8%), with no progression-free or overall survival benefit. WB-DW-MRI proved feasible for response monitoring, though it was unevaluable in 17 cases.
Like
Save
Share